The AMPK enzyme-complex: From the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders

Expert Opinion on Therapeutic Targets

Volumn 20, Issue 2, 2016, Pages 179-191

  Antonioli, Luca ^a   Colucci, Rocchina ^a   Pellegrini, Carolina ^a   Giustarini, Giulio ^a   Sacco, Deborah ^a   Tirotta, Erika ^a   Caputi, Valentina ^b   Marsilio, Ilaria ^b   Giron, Maria Cecilia ^b   Németh, Zoltán H ^c,d   Blandizzi, Corrado ^a   Fornai, Matteo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c MORRISTOWN MEDICAL CENTER   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Adenosine; Adenosine monophosphate activated protein kinase; Adenosine triphosphate; Dendritic cells; Immune system; Inflammation; Inflammatory disease; Lymphocytes; Macrophages; Neutrophils

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; ATORVASTATIN; BERBERINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; QUERCETIN; RESVERATROL; ANTIINFLAMMATORY AGENT;

ALPHA CHAIN; ATHEROSCLEROSIS; BETA CHAIN; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CHRONIC INFLAMMATORY DISORDER; DEGENERATIVE DISEASE; DENDRITIC CELL; DISEASE ASSOCIATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MACROPHAGE; MEMORY T LYMPHOCYTE; NONHUMAN; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; CHRONIC DISEASE; DRUG DESIGN; ENZYMOLOGY; HOMEOSTASIS; HUMAN; INFLAMMATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHRONIC DISEASE; DRUG DESIGN; HOMEOSTASIS; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY;

EID: 84957948346     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2016.1086752     Document Type: Review

References (103)

1. Nathan C. Points of control in inflammation. Nature 2002;420:846-52
2. Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts in immunity and inflammation. J Immunol 2010;184:4062-8
3. Medikayala S, Piteo B, Zhao X, et al. Chronically elevated glucose compromises myocardial mitochondrial DNA integrity by alteration of mitochondrial topoisomerase function. Am J Physiol Cell Physiol 2011;300:C338-48
4. Clinard F, Sgro C, Bardou M, et al. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/noncase study from the French Pharmacovigilance system database. Eur J Clin Pharmacol 2004;60:279-83
5. Conaghan PG. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012;32:1491-502
6. Glintborg B. Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine. Ugeskr Laeger 2000;162:4553-4
7. Gilani ST, Khan DA, Khan FA, et al. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak 2012;22:101-4
8. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008;32:S7-12
9. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013;493:346-55
10. Salminen A, Hyttinen JM, Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011;89:667-76
11. Salt IP, Palmer TM. Exploiting the antiinflammatory effects of AMP-activated protein kinase activation. Expert Opin Investig Drugs 2012;21:1155-67
12. Hardie DG, Scott JW, Pan DA, et al. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003;546:113-20
13. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004;29:18-24
14. Woods A, Salt I, Scott J, et al. The alpha1 and alpha2 isoforms of the AMPactivated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett 1996;397:347-51
15. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996;271:611-14
16. Woods A, Cheung PC, Smith FC, et al. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem 1996;271:10282-90
17. Carling D, Hardie DG. The substrate and sequence specificity of the AMPactivated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta 1989;1012:81-6
18. Nielsen JN, Wojtaszewski JF, Haller RG, et al. Role of 5'AMP-activated protein kinase in glycogen synthase activity and glucose utilization: insights from patients with McArdle's disease. J Physiol 2002;541:979-89
19. Xiao B, Heath R, Saiu P, et al. Structural basis for AMP binDing to mammalian AMP-activated protein kinase. Nature 2007;449:496-500
20. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004;101:3329-35
21. Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005;2:9-19
22. Hattori Y, Nakano Y, Hattori S, et al. High molecular weight adiponectin activates AMPK and suppresses cytokineinduced NF-kappaB activation in vascular endothelial cells. FEBS Lett 2008;582:1719-24
23. Oakhill JS, Scott JW, Kemp BE. Structure and function of AMP-activated protein kinase. Acta Physiol (Oxf) 2009;196:3-14
24. Ning J, Xi G, Clemmons DR. Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology 2011;152:3143-54
25. Russo GL, Russo M, Ungaro P. AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem Pharmacol 2013;86:339-50
26. Marsin AS, Bouzin C, Bertrand L, et al. The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase. J Biol Chem 2002;277:30778-83
27. Gruzman A, Babai G, Sasson S. Adenosine monophosphate-activated protein kinase (ampk) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 2009;6:13-36
28. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
29. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226-32
30. Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006;114:2655-62
31. Choi HC, Song P, Xie Z, et al. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J Biol Chem 2008;283:20186-97
32. Mooney MH, Fogarty S, Stevenson C, et al. Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice. Br J Pharmacol 2008;153:1669-77
33. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008;57:1414-18
34. Amatya PN, Kim HB, Park SJ, et al. A role of DNA-dependent protein kinase for the activation of AMP-activated protein kinase in response to glucose deprivation. Biochim Biophys Acta 2012;1823:2099-108
35. Kim DH, Joo JI, Choi JW, et al. Differential expression of skeletal muscle proteins in high-fat diet-fed rats in response to capsaicin feeDing. Proteomics 2010;10:2870-81
36. Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 2009;296:E812-19
37. Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin antiinflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NFkappaB pathway. Eur J Immunol 2005;35:584-92
38. Ahn J, Lee H, Kim S, et al. The antiobesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun 2008;373:545-9
39. Lu J, Wu DM, Zheng YL, et al. Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. J Pathol 2010;222:199-212
40. Gadalla AE, Pearson T, Currie AJ, et al. AICA riboside both activates AMPactivated protein kinase and competes with adenosine for the nucleoside transporter in the CA1 region of the rat hippocampus. J Neurochem 2004;88:1272-82
41. Corton JM, Gillespie JG, Hawley SA, et al. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558-65
42. Merrill GF, Kurth EJ, Hardie DG, et al. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997;273:E1107-12
43. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-37
44. Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004;76:509-13
45. Jhun BS, Jin Q, Oh YT, et al. 5- Aminoimidazole-4-carboxamide riboside suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of phosphatidylinositol 3-kinase/Akt activation in RAW 264.7 murine macrophages. Biochem Biophys Res Commun 2004;318:372-80
46. Sag D, Carling D, Stout RD, et al. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008;181:8633-41
47. Lee HM, Kim JJ, Kim HJ, et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013;62:194-204
48. Palsson-McDermott EM, O'Neill LA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays 2013;35:965-73
49. Jeong HW, Hsu KC, Lee JW, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 2009;296:E955-64
50. Chang MY, Ho FM, Wang JS, et al. AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-beta-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway. Biochem Pharmacol 2010;80:1210-20
51. Bae HB, Zmijewski JW, Deshane JS, et al. AMP-activated protein kinase enhances the phagocytic ability of macrophages and neutrophils. FASEB J 2011;25:4358-68
52. Fracchia KM, Pai CY, Walsh CM. Modulation of T Cell Metabolism and Function through Calcium Signaling. Front Immunol 2013;4:324
53. Notarangelo LD. Combined immunodeficiencies with nonfunctional T lymphocytes. Adv Immunol 2014;121:121-90
54. Stefanelli C, Stanic I, Bonavita F, et al. Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4- carboxamide ribonucleoside, a cellpermeable activator of AMP-activated protein kinase. Biochem Biophys Res Commun 1998;243:821-6
55. Tamas P, Hawley SA, Clarke RG, et al. Regulation of the energy sensor AMPactivated protein kinase by antigen receptor and Ca2+ in T lymphocytes. J Exp Med 2006;203:1665-70
56. Bhavsar SK, Schmidt S, Bobbala D, et al. AMPKalpha1-sensitivity of Orai1 and Ca(2+) entry in T - lymphocytes. Cell Physiol Biochem 2013;32:687-98
57. Mayer A, Denanglaire S, Viollet B, et al. AMP-activated protein kinase regulates lymphocyte responses to metabolic stress but is largely dispensable for immune cell development and function. Eur J Immunol 2008;38:948-56
58. Tamas P, Macintyre A, Finlay D, et al. LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol 2010;40:242-53
59. Blagih J, Krawczyk CM, Jones RG. LKB1 and AMPK: central regulators of lymphocyte metabolism and function. Immunol Rev 2012;249:59-71
60. Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103-7
61. Rolf J, Zarrouk M, Finlay DK, et al. AMPKalpha1: a glucose sensor that controls CD8 T-cell memory. Eur J Immunol 2013;43:889-96
62. Nauseef WM, Borregaard N. Neutrophils at work. Nat Immunol 2014;15:602-11
63. Lomas-Neira J, Chung CS, Perl M, et al. Role of alveolar macrophage and migrating neutrophils in hemorrhageinduced priming for ALI subsequent to septic challenge. Am J Physiol Lung Cell Mol Physiol 2006;290:L51-8
64. Zhao X, Zmijewski JW, Lorne E, et al. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. Am J Physiol Lung Cell Mol Physiol 2008;295:L497-504
65. Alba G, El Bekay R, Alvarez-Maqueda M, et al. Stimulators of AMP-activated protein kinase inhibit the respiratory burst in human neutrophils. FEBS Lett 2004;573:219-25
66. Tadie JM, Bae HB, Deshane JS, et al. Toll-like receptor 4 engagement inhibits adenosine 5'-monophosphate-activated protein kinase activation through a high mobility group box 1 protein-dependent mechanism. Mol Med 2012;18:659-68
67. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811
68. Krawczyk CM, Holowka T, Sun J, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010;115:4742-9
69. Nurbaeva MK, Schmid E, Szteyn K, et al. Enhanced Ca(2)(+) entry and Na+/Ca(2)(+) exchanger activity in dendritic cells from AMP-activated protein kinasedeficient mice. FASEB J 2012;26:3049-58
70. Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60
71. Ha HL, Wang H, Pisitkun P, et al. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc Natl Acad Sci U S A 2014;111:E3422-31
72. Li W, Ma W, Zhong H, et al. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med 2014;7:389-92
73. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res 2007;149:173-86
74. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol 2005;175:6900-8
75. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34
76. Scharl M, Paul G, Barrett KE, et al. AMP-activated protein kinase mediates the interferon-gamma-induced decrease in intestinal epithelial barrier function. J Biol Chem 2009;284:27952-63
77. Bai A, Yong M, Ma AG, et al. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J Pharmacol Exp Ther 2010;333:717-25
78. Bai A, Ma AG, Yong M, et al. AMPK agonist downregulates innate and adaptive immune responses in TNBSinduced murine acute and relapsing colitis. Biochem Pharmacol 2010;80:1708-17
79. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6
80. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108
81. Tong KM, Chen CP, Huang KC, et al. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 2011;112:1431-40
82. Tang CH, Chiu YC, Tan TW, et al. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NFkappa B pathway. J Immunol 2007;179:5483-92
83. Terkeltaub R, Yang B, Lotz M, et al. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin- 1beta and tumor necrosis factor alpha. Arthritis Rheum 2011;63:1928-37
84. Tousoulis D, Kampoli AM, Papageorgiou N, et al. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des 2011;17:4089-110
85. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74
86. Ewart MA, Kennedy S. AMPK and vasculoprotection. Pharmacol Ther 2011;131:242-53
87. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009;105:114-27
88. Wang Q, Zhang M, Liang B, et al. Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One 2011;6:e25436
89. Dong Y, Zhang M, Liang B, et al. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 2010;121:792-803
90. Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMPactivated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006;55:2180-91
91. Fullerton MD, Steinberg GR, Schertzer JD. Immunometabolism of AMPK in insulin resistance and atherosclerosis. Mol Cell Endocrinol 2013;366:224-34
92. Ishii N, Matsumura T, Kinoshita H, et al. Activation of AMP-activated protein kinase suppresses oxidized lowdensity lipoprotein-induced macrophage proliferation. J Biol Chem 2009;284:34561-9
93. Li D, Wang D, Wang Y, et al. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 2010;285:33499-509
94. Li Y, Xu S, Jiang B, et al. Activation of sterol regulatory element binDing protein and NLRP3 inflammasome in atherosclerotic lesion development in diabetic pigs. PLoS One 2013;8:e67532
95. Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in dietinduced insulin-resistant mice. Cell Metab 2011;13:376-88
96. Ju TC, Lin YS, Chern Y. Energy dysfunction in Huntington's disease: insights from PGC-1alpha, AMPK, and CKB. Cell Mol Life Sci 2012;69:4107-20
97. Bossy-Wetzel E, Petrilli A, Knott AB. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 2008;31:609-16
98. Khatri N, Man HY. Synaptic activity and bioenergy homeostasis: implications in brain trauma and neurodegenerative diseases. Front Neurol 2013;4:199
99. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem 2010;47:69-84
100. Vingtdeux V, Giliberto L, Zhao H, et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010;285:9100-13
101. Tong X, Smith KA, Pelling JC. Apigenin, a chemopreventive bioflavonoid, induces AMP-activated protein kinase activation in human keratinocytes. Mol Carcinog 2012;51:268-79
102. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. Annu Rev Nutr 2014;34:31-55
103. Nath N, Khan M, Rattan R, et al. Loss of AMPK exacerbates experimental autoimmune encephalomyelitis disease severity. Biochem Biophys Res Commun 2009;386:16-20